Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Radezolid · 2 trials · 6 indications
To qualify as a Cure, participants were required to fulfill the following criteria: all systemic signs and symptoms of uSSSI present at screening were improved or resolved; no further antibiotic therapy was necessary for treatment of uSSSI; and there was no worsening or appearance of new signs and symptoms of uSSSI.
Patients were considered cured if all systemic signs and symptoms of CAP present at screening were improved or resolved and no further antibiotic therapy was necessary. In addition, the follow-up chest X-ray was to be either stable or improved.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Radezolid 450 mg PO QD |
| 2 | EXPERIMENTAL | Radezolid 450 mg PO BID |
| 3 | ACTIVE_COMPARATOR | Linezolid 600 mg PO BID |
| Name | Type | Description |
|---|---|---|
| Radezolid | DRUG | 450mg PO QD |
| Linezolid | DRUG | 600mg PO BID |
Inclusion Criteria: * Adult patients with uSSSI * Adult (men and women) ≥18 years * Females must be post-menopausal for at least 1 year or surgically sterile * Sexually active males must use a barrier method of birth control during and for 30 days after the study * Acceptable clinical diagnoses of ...
Radezolid is an investigational small molecule antibiotic being studied for the treatment of community-acquired pneumonia (CAP) and infectious skin diseases, including bacterial skin infections, staphylococcal skin infections, streptococcal infections, and abscesses. It is being developed by CorMedix Inc. (CRMD) and is currently in Phase 2 clinical development.
Radezolid is an oxazolidinone antibiotic, a class of drugs that works by inhibiting bacterial protein synthesis. It is being studied for use against bacterial infections, including those affecting the skin and respiratory tract. The specific molecular target of Radezolid has not been disclosed in the available clinical trial information.
Radezolid is being developed by CorMedix Inc., a biopharmaceutical company traded on the NYSE American under the ticker symbol CRMD. The company is conducting clinical trials to evaluate the safety and efficacy of Radezolid for the treatment of infectious diseases.
Radezolid is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. Two Phase 2 clinical trials have been completed, one for community-acquired pneumonia and one for uncomplicated skin infections, but Radezolid remains in the clinical development stage.
Radezolid has been studied in two completed Phase 2 clinical trials. The first, NCT00640926, evaluated its safety and efficacy in treating community-acquired pneumonia in 158 participants across the United States, Canada, and Russia. The second, NCT00646958, studied its use in uncomplicated skin infections in 150 participants in the United States.
Radezolid is an oxazolidinone antibiotic, a class of synthetic antibacterial agents. It is being studied for its potential to treat bacterial infections, including community-acquired pneumonia and skin infections. Radezolid is distinct from other oxazolidinones like linezolid, though it shares the same class mechanism of action.